In an otherwise healthy woman over 50 with uncomplicated hypertension, is chlorthalidone an appropriate first-line therapy?

Yes, chlorthalidone is an excellent first-line choice for uncomplicated hypertension in women over 50.

Chlorthalidone is explicitly recommended as a first-line agent for uncomplicated hypertension in this population, with Grade A evidence supporting thiazide/thiazide-like diuretics as preferred initial therapy 1, 2, 3. The most recent 2024 ESC guidelines specifically list "thiazides and thiazide-like drugs such as chlorthalidone and indapamide" as first-line treatments that have demonstrated the most effective reduction of BP and cardiovascular events 4.

Why Chlorthalidone Specifically?

Chlorthalidone is preferred over hydrochlorothiazide (HCTZ) due to its longer duration of action and superior 24-hour blood pressure control, particularly overnight 5. The 2020 Hypertension Canada guidelines explicitly state that "longer-acting diuretics [are] preferred" (Grade B) 1, and the AHA Scientific Statement on Resistant Hypertension recommends chlorthalidone or indapamide as preferred thiazide diuretics over HCTZ 6.

The FDA-approved dosing for hypertension starts at 25 mg once daily, which can be increased to 50 mg if response is insufficient, with 100 mg as the maximum effective dose 7.

Evidence Quality and Nuances

However, recent head-to-head trials have challenged the superiority of chlorthalidone over HCTZ. The 2020 LEGEND study found no significant difference in cardiovascular outcomes between the two agents (calibrated HR 1.00,95% CI 0.85-1.17) 8. The 2025 ACC/AHA guidelines note that a large pragmatic RCT comparing HCTZ 25 mg to chlorthalidone 12.5 mg showed no difference in major adverse cardiovascular events 9.

The critical trade-off is safety: Chlorthalidone consistently demonstrates higher rates of:

• Hypokalemia (HR 2.72-3.06) 10, 8, 11
• Hyponatremia (HR 1.31-1.68) 10, 8, 11
• Acute kidney injury (HR 1.37) 8
• Need for potassium supplementation 10

Practical Algorithm for Use

Start with chlorthalidone 12.5-25 mg once daily in the morning with food 7:

1. Check baseline electrolytes and renal function before initiation
2. Recheck within 2-4 weeks after starting or dose escalation 12
3. Monitor for hypokalemia - this is dose-related over the 25-100 mg range 7
4. Avoid hypokalemia per Grade C recommendation 1, 2, 3
5. If electrolyte abnormalities develop, consider switching to HCTZ or adding potassium supplementation

For women over 50 specifically, thiazide diuretics are particularly appropriate as:

• Beta-blockers are NOT recommended as first-line in patients ≥60 years (Grade A) 1, 2, 3
• This age group often has isolated systolic hypertension, where thiazides have Grade A evidence 1, 3

Alternative First-Line Options

If chlorthalidone is not tolerated or contraindicated, equally acceptable first-line alternatives include 1, 2, 4:

• Long-acting dihydropyridine calcium channel blockers (Grade A/B)
• ACE inhibitors in non-Black patients (Grade B)
• ARBs (Grade B)

Most patients will require combination therapy to reach target BP <140/90 mmHg 1. The preferred combinations are thiazide + ACE inhibitor/ARB, or thiazide + calcium channel blocker (Grade B) 1, 2.

Common Pitfalls

• Don't automatically discontinue when eGFR drops below 30 mL/min/1.73 m² - chlorthalidone can still be effective in advanced CKD 12
• Don't combine with loop diuretics without close potassium monitoring 12
• Don't use in pregnancy - diuretics are inappropriate for routine use in otherwise healthy pregnant women 7
• Watch for drug interactions that increase hypokalemia risk (corticosteroids, amphotericin B)

The bottom line: Chlorthalidone remains guideline-recommended as first-line therapy, but requires vigilant electrolyte monitoring, particularly in older adults 1, 2, 4.